Continuing temozolomide after 6 adjuvant cycles: greater toxicity but no additional benefit in 6-month progression-free survival of patients with glioblastoma



Background: Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate. We performed a phase II randomized trial investigating whether extending adjuvant temozolomide for more than 6 cycles improved outcome.

Methods: Glioblastoma patients treated at 20 Spanish hospitals who had not progressed after 6 cycles of adjuvant temozolomide were centrally randomized to stop (control arm) or continue (experimental arm) temozolomide up to a total of 12 cycles at the same doses they were receiving in cycle 6. © 2020 Society for Neuro-Oncology. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries. Published in the United States by Oxford University Press USA, New York. This article is published with permission from Oxford University Press.
All rights reserved. No part of this article may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, or under
terms agreed with the appropriate reprographics rights organization.

Enquiries concerning reproduction outside the scope of the above should be sent to the Academic Rights Department, Oxford University Press, Oxford, UK.
Oxford University Press makes no representation, express or implied, that the drug dosages in this article are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.
The ultimate responsibility for the use and dosage of drugs mentioned in this article, and in interpretation of published material, lies with the medical practitioner. Please inform Biogen MA Inc of any actual or suspected errors contained in this article.
The mention of trade names, commercial products or organizations, and/or the inclusion of advertisements in this Translation does not imply a guarantee, recommendation or endorsement of any kind by Oxford University Press or its authors or editors.